Mitsubishi Tanabe Pharma to transfer ingredient manufacturing to API

Published: 23-May-2012
Ingredients Finance

Will focus on drug discovery and development


Mitsubishi Tanabe Pharma (MTP) is to pull out of the fine chemicals industry and transfer all pharmaceutical ingredient manufacturing to a subsidiary.

The Japanese firm will transfer pharmaceutical ingredient manufacturing and sales operations to API Corporation in Osaka, while food chemical operations will go to Taisho Technos in Tokyo.

API is a subsidiary of Mitsubishi Chemical Corporation, whose business is centred on healthcare and fine chemicals. The firm says it aims to become a ‘creative, r&d-oriented company in the field of speciality fine chemicals’ and contribute to a ‘higher quality of life for people throughout the world’.

Taisho Technos is a subsidiary of Mitsui Sugar and aims to achieve sustainable growth while developing its core businesses of manufacturing and selling food additives, as well as preservatives and anti-fungal agents for industrial use.

Mitsubishi Tanabe Pharma says it aims to focus management resources on its pharmaceutical operations, including the ‘discovery and global provision of new drugs that respond to unmet medical needs’.

The firm hopes to achieve this by bolstering its ability to discover new drugs; focus domestic operations on new products; build a foundation for the expansion of overseas operations; and accelerate operational and structural reforms.

  • Companies:
  • Mitsubishi Group
See more

You may also like

Finance

New joint venture to lead digital manufacturing into a new era

Read more
Mitsubishi Electric Corporation and Visual Components are combining capabilities to establish ME Industrial Simulation Software Corporation, a robotics and automation simulation software company,

Trending Articles

  1. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  2. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Finance

New joint venture to lead digital manufacturing into a new era

Mitsubishi Electric Corporation and Visual Components are combining capabilities to establish ME Industrial Simulation Software Corporation, a robotics and automation simulation software company,
Drug Delivery

Roquette finalises Qualicaps acquisition for pharmaceutical excipient growth

Roquette has acquired Qualicaps, the manufacturer of hard capsules and pharmaceutical-related equipment and the third-largest producer of hard capsules for oral dosage solutions
Manufacturing

Mitsubishi signs agreement with Roquette for Qualicaps shares

Pharmaceutical excipients expert Roquette has signed an agreement with the MCG Group for the shares of hard capsule manufacturer Qualicaps
Ingredients

Mitsubishi Chemical Holdings to acquire Qualicaps from Carlyle

Qualicaps has increased revenue by more than 50% since Carlyle took over in 2005
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Let enzymes do the work

The use of enzyme catalysts has had a real impact on the synthesis of pharmaceutical ingredients, making it possible to improve some syntheses dramatically and even make some molecules that would otherwise be either impossible or impractical to synthesise. The use of flow reactors in biocatalysis faces challenges arising from the heterogeneous slurry nature of the reaction mixture and problems with gas and liquid handling. But research is being carried out into continuous manufacturing methods for biocatalytic reactions.
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Subscribe now